Tissue Regenix Group Plc

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
G8887U107
SEDOL
B5SGVL2
CIK
N/A
www.tissueregenix.com
LEI:
©
FIGI: -
TRX
Tissue Regenix Group Plc
GICS: - · Sector: - · Sub-Sector: -
AI
PROFILER
NAME
Tissue Regenix Group Plc
ISIN
GB00B5SGVL29
TICKER
TRX
MIC
XLON
REUTERS
TRX.L
BLOOMBERG
TRX LN
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Mon, 23.09.2024

Hardman & Co Research on Tissue Regenix (TRX): Maiden pre-tax profit   TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of products used in biosurgery, orthopaedics and dental markets. Investment in tissue ...
Research & Analysis
Read more
Mon, 23.09.2024

Hardman & Co Research on Tissue Regenix (TRX): Maiden pre-tax profit   TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of products used in biosurgery, orthopaedics and dental markets. Investment in tissue ...
Research & Analysis
Read more
Tue, 25.06.2024

Hardman & Co Insight: Survival of the UK life sciences sector   For two years running, the Hardman & Co Healthcare index has declined, underperforming both the FTSE 100 and the FTSE All-Share indices. This is quite unusual for healthcare stocks. Apart from the general economic influences, which have made institutions more risk-averse, the...
Research & Analysis
Read more
Wed, 10.04.2024

Hardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth   TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of products used in biosurgery, orthopaedics and dental markets. I...
Research & Analysis
Read more
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S